tiprankstipranks
Trending News
More News >
Ab Science (ABSCF)
:ABSCF
Advertisement

AB Science SA (ABSCF) Price & Analysis

Compare
15 Followers

ABSCF Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

100.00%
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors

ABSCF FAQ

What was Ab Science’s price range in the past 12 months?
Ab Science lowest stock price was $0.80 and its highest was $2.70 in the past 12 months.
    What is Ab Science’s market cap?
    Ab Science’s market cap is $93.86M.
      When is Ab Science’s upcoming earnings report date?
      Ab Science’s upcoming earnings report date is Sep 30, 2025 which is in 73 days.
        How were Ab Science’s earnings last quarter?
        Currently, no data Available
        Is Ab Science overvalued?
        According to Wall Street analysts Ab Science’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Ab Science pay dividends?
          Ab Science does not currently pay dividends.
          What is Ab Science’s EPS estimate?
          Ab Science’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Ab Science have?
          Ab Science has 61,428,642 shares outstanding.
            What happened to Ab Science’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Ab Science?
            Currently, no hedge funds are holding shares in ABSCF

            Company Description

            Ab Science

            AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
            Similar Stocks
            Company
            Price & Change
            Follow
            Innate Pharma SA
            Transgene
            OSE Immunotherapeutics SA
            Sensorion SAS
            ABL Diagnostics SA
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis